A methodology to extract outcomes from routine healthcare data for patients with locally advanced non-small cell lung cancer

Swee-Ling Wong¹*, Kate Ricketts², Gary Royle³, Matt Williams⁴,⁵ and Ruheena Mendes¹

Abstract

Background: Outcomes for patients in UK with locally advanced non-small cell lung cancer (LA NSCLC) are amongst the worst in Europe. Assessing outcomes is important for analysing the effectiveness of current practice. However, data quality is inconsistent and regular large scale analysis is challenging. This project investigates the use of routine healthcare datasets to determine progression free survival (PFS) and overall survival (OS) of patients treated with primary radical radiotherapy for LA NSCLC.

Methods: All LA NSCLC patients treated with primary radical radiotherapy in a 2 year period were identified and paired manual and routine data generated for an initial pilot study. Manual data was extracted from hospital records and considered the gold standard. Key time points were date of diagnosis, recurrence, death or last clinical encounter. Routine data was collected from various data sources including, Hospital Episode Statistics, Personal Demographic Service, chemotherapy data, and radiotherapy datasets. Relevant event dates were defined by proxy time points and refined using backdating and time interval optimization. Dataset correlations were then tested on key clinical outcome indicators to establish if routine data could be used as a reliable proxy measure for manual data.

Results: Forty-three patients were identified for the pilot study. The manual data showed a median age of 67 years (range 46–89 years) and all patients had stage IIIA/B disease. Using the manual data, the median PFS was 10.78 months (range 1.58–37.49 months) and median OS was 16.36 months (range 2.69–37.49 months). Based on routine data, using proxy measures, the estimated median PFS was 10.68 months (range 1.61–31.93 months) and estimated median OS was 15.38 months (range 2.14–33.71 months). Overall, the routine data underestimated the PFS and OS of the manual data but there was good correlation with a Pearson correlation coefficient of 0.94 for PFS and 0.97 for OS.

Conclusions: This is a novel approach to use routine datasets to determine outcome indicators in patients with LA NSCLC that will be a surrogate to analysing manual data. The ability to enable efficient and large scale analysis of current lung cancer strategies has a huge potential impact on the healthcare system.

Keywords: LA NSCLC, Outcomes, Routine datasets

* Correspondence: swee.wong@nhs.net
¹Department of Clinical Oncology, University College London Hospital, 235 Euston Road, London NW1 2BU, UK
Full list of author information is available at the end of the article

© The Author(s), 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Lung cancer is a leading cause of cancer-related mortality world-wide with approximately 70% of patients presenting with locally advanced or metastatic disease [1]. In the UK, outcomes for patients with LA NSCLC are amongst the worst in Europe and local recurrence occurs in up to 50% of patients despite improvements in 5 year survival [2, 3]. This has highlighted a need to not only identify causes of this deficit and advance treatment strategies, but a need for frequent large scale analysis of outcomes to assess the effectiveness of such treatments.

Radiotherapy plays an important role in the treatment of patients with locally advanced disease and national cancer strategies have been implemented to incentivise centres to formally assess radiotherapy outcomes with the introduction of an outcomes-based commissioning framework [4]. As a result, there is a recognised need to be able to assess, qualify and quantify the quality of radiotherapy practice which is valuable for research and strategic planning of service provision.

Progression free survival (PFS) and overall survival (OS) are key outcome measures for lung cancer that are important assessment tools of the effectiveness of an institution’s lung cancer strategy. PFS has become an increasingly important outcome measure in clinical trials, used as a surrogate for OS that is less influenced by subsequent therapies, and important for evaluating treatment response. Measuring PFS is in itself a challenge due to an inconsistency of definition and use in the literature and measurement accuracy [5, 6]. To reliably determine these outcomes measures, the quality, completeness and consistency of data recording is important as well as the ability to efficiently interpret these. Manually collected prospective data taken from patients’ notes, as collected in trials, is considered the gold standard in most accurately identifying clinically significant dates for patients’ investigation and management pathways. However, data quality can be inconsistent and collecting it is labour-intensive, making assessment of large numbers time-consuming. Routine datasets are nationally collected patient data, including hospital episodes statistic (HES), radiotherapy database (RTDS), systemic anti-cancer therapy (SACT) and personal demographics service (PDS).

Information from routinely collected electronic datasets is inexpensive and its use in population-based studies to investigate disease incidence, mortality and public health issues has long been established. There has been growing interest in using routine data to assess clinical outcomes [7], particularly in cancer management, in the hope that regular feedback will facilitate improved outcomes [8–12]. Whilst dates of diagnosis and recurrence may not be directly captured in the data it is possible to identify information to serve as surrogates for these relevant time points and Ricketts et al. recently demonstrated that routine data could be used to estimate OS and PFS in patients with head and neck cancers treated with radical radiotherapy [13, 14].

The aim of this paper is to develop and optimise a methodology to extract OS and PFS from routinely collected electronic health care data for patients treated with primary radical radiotherapy for LA NSCLC that will enable information to be evaluated effectively and efficiently.

Methods
All patients with LA NSCLC, taken to be any patient with stage IIIA/B disease (Additional file 1), treated with primary radical radiotherapy in a 2 year period (August 2013 to August 2015) in University College London Hospital, a regional referral centre, were identified for this initial pilot study of 43 patients.

For each patient, paired manual and routine datasets were generated to compare OS and PFS, based on manual data, with estimated OS and PFS based on routine data.

Manual dataset
The manual data was extracted from hospital notes which included clinic letters, multidisciplinary team (MDT) meetings, histopathology and radiology reports, and chemotherapy and radiotherapy treatment records. The relevant time points required to calculate PFS and OS were the date of diagnosis, recurrence, and death or last known appointment.

a. Manual diagnosis date: The diagnostic biopsy date was chosen to most accurately represent the date of diagnosis as this is when histological confirmation of disease is obtained. If the biopsy date was not available (eg. if the biopsy was performed in a different hospital) then other dates were used following a hierarchy, as defined by the UK National Lung Cancer Audit, of date of: i) imaging in the form of CT (computed tomography) and PET CT (positron emissions tomography CT) ii) admission to hospital due to this malignancy iii) patient’s evaluation at an out-patient clinic relating to this malignancy and iv) referral [15] (Table 1).

Manual recurrence date: The recurrence date was taken to be the date of recognized progression, recurrence, metastases, death, or last known clinical encounter (if no progression occurred). Progression, recurrence or metastatic disease was determined by dates of any investigative procedure, including radiological scans or biopsies, which first positively identified disease recurrence (Table 1).
Routine dataset

Routine data was collected from HES, SACT, RTDS, and PDS (Table 2).

Surrogates were identified as suitable proxy measures for dates of diagnosis and recurrence events (Table 1).

Table 1 Definitions of key time points used to calculate PFS and OS for manual data and the ICD-10 (international classification of diseases) and OPCS (Office of population censuses and surveys classification of surgical operations and procedures) codes used for diagnosis and recurrence flag events from the routine data

| Time points       | Definitions for manual data                                                                 | Definitions for routine data                                                                 |
|-------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| **Diagnosis date**| In order of preference [13]:  
❖ Date of first histological or cytological confirmation of malignancy.  
- date when specimen taken  
- date of receipt by pathologist  
- date of pathology report  
❖ Date of imaging from a CT, PET scan or other form of clinical diagnosis  
❖ Date of admission to hospital because of this malignancy.  
❖ When evaluated at an oncology out-patient clinic only: date of first consultation at out-patient clinic because of this malignancy  
❖ Date of referral  
| HES               | ❖ Date of biopsy (taken as the optimal date of diagnosis) within pre-specified time window of X weeks of treatment initiation  
If not available, then the earliest within a pre-specified time window of X weeks of treatment initiation:  
❖ First relevant ICD10 code (Additional file 4)  
❖ OPCS identifying relevant time points and proxy measures for investigation (Additional file 2) and management (Additional file 3)  
| RTDS              | ❖ Date of request on booking form consent date for secondary treatment. (This date must correspond to treatment that is also documented in the RTDS with “Category: Radical”)  
| SACT              | ❖ Start date  
|                   | The earliest within a pre-specified time window of X weeks of *secondary treatment initiation:  
|                   | ❖ ICD10 codes for secondary malignancies (Additional file 5)  
❖ OPCS and ICD10 codes identifying relevant time points and proxy measures for recurrent, progressive or metastatic disease investigation (Additional file 6).  
| RTDS              | ❖ Date of request on booking form consent date. (This date must correspond to treatment that is also documented in the RTDS with “Category: Palliative”)  
If there are no secondary treatment codes (Additional file 7) but there are ICD10 codes for secondary malignancies (Additional file 5), these can be used to identify recurrence dates.  
If there are no ICD10 codes for secondary malignancies or investigative procedures then the start date of secondary treatment can be used:  
|                   | ❖ OPCS identifying secondary management for recurrent, progressive or metastatic disease (Additional file 7)  
|                   | ❖ Start date  
|                   | ❖ Start date  
|                   | ❖ Date of recorded death on PDS  
|                   | ❖ Date of recorded death from medical notes or clinical letters  
|                   | ❖ Last known clinical encounter with any specialty (in the hospital or community) based on clinical letters or letters of correspondence from the patient or their next of kin  
|                   | ❖ Date of last HES, SACT, RTDS entry.  

* Secondary treatment is defined as any treatment being initiated 10 weeks following completion of primary treatment, identified using relevant codes (Additional file 7)
Table 2  Routine datasets. This shows the national datasets available for analysis, their intended function and the patient-specific information that can be collected from the different databases

| Routine dataset                                      | Information available                                                                 |
|------------------------------------------------------|---------------------------------------------------------------------------------------|
| PDS (Personal Demographics Service)                  | • Name                                                                                 |
|                                                       | • Address                                                                              |
|                                                       | • Date of birth                                                                        |
|                                                       | • NHS Number                                                                           |
|                                                       | • Date of death                                                                        |
| HES (Hospital Episodes Statistics)                    | • Dates of all hospital encounters including admissions and discharge dates, outpatient appointments, and A&E attendances. |
|                                                       | • Diagnoses                                                                            |
|                                                       | • Operations                                                                          |
|                                                       | • Age group                                                                            |
|                                                       | • Gender                                                                               |
|                                                       | • Ethnicity                                                                            |
|                                                       | • Area of patient’s residence                                                         |
| SACT (Systemic Anti-Cancer Therapy)                   | • Demographics- including commissioner and provider initiating treatment               |
|                                                       | • Clinical status-diagnosis, performance status, treatment intent                     |
|                                                       | • Programme and regimen- drug details, cycle and regime number, supportive medications, treatment dates |
|                                                       | • Outcome- regimen modification eg. dose reductions, cycle delays, early termination of treatment, and outcome summary. |
| RTDS (Radiotherapy Dataset)                           | • Demographics- commissioner and provider initiating treatment                         |
|                                                       | • Clinical status-diagnosis, treatment intent, history of previous radiotherapy (diagnosis relating to that treatment, treatment intent, dose, fractionation, site treated, dates of referral and of treatment), |
|                                                       | • Dose prescription- dose and fractionation regime, treatment site                     |
|                                                       | • Outcome- actual dose delivered, treatment dates                                      |

a. Routine diagnosis date: This was taken to be the corresponding date of biopsy OPCS codes (Additional file 2) (available for all patients investigated within our centre), so long as it fell within a pre-specified time window of x weeks of lung cancer treatment initiation (Additional file 3) (see section “Interval definitions for back-dating”). If biopsy codes were not found on routine data, proxy time points were used as surrogates as long as they occurred within this pre-specified time window from start of primary treatment: the earliest of (i) the first relevant ICD10 codes denoting lung malignancy (Additional file 4) or (ii) other investigative OPCS codes (Additional file 2).

b. Routine recurrence date: The date of progression, recurrence or metastases was identified using (i) ICD 10 codes for secondary malignancies (Additional file 5) or investigative procedures (Additional file 6) which occurred within a pre-specified time window prior to secondary treatment (Additional file 7) initiation (ii) ICD10 codes identifying secondary malignancies if no secondary treatment codes appeared (iii) the start date of secondary treatment if no ICD10 codes for secondary malignancies or investigative procedures were seen on routine data.

Secondary treatment was defined as any treatment event occurring more than 10 weeks after the end of primary treatment (last day of radiotherapy or chemotherapy, whichever occurred last) and further identified by OPCS codes in Additional file 7.

Survival intervals
PFS was taken to be the time interval between the diagnosis date and the date of progression, recurrence or metastases. If no progression occurred the date of last known clinical encounter or death was used.

OS was taken to be the time interval between the diagnosis date to the date of death from any cause or date of last known clinical encounter (if the patient was still alive at the time of analysis).

Key code tables were generated to aid interpretation of the routine data (Additional files 2, 3, 4, 5, 6 and 7), enabling the identification of codes signifying the relevant time points. The datasets were analysed separately in this manner and then merged to create a timeline.
**Code identification and classification**

Codes were identified and sorted according to diagnostic ICD 10 codes consistent with lung malignancy (Additional files 4 and 5) and OPCS codes consistent with diagnostic investigations (including biopsies and CT or CT PET imaging) (Additional files 2 and 6) and management strategies (Additional files 3 and 7), separated into radiotherapy, chemotherapy and interventional treatment.

a. ICD-10 codes indicating primary site lung malignancies (Additional file 4)

All codes relating to “malignant neoplasm of bronchus or lung” [C34], “malignant neoplasm of heart, mediastinum and pleura” [C38], and “Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes” [C77.1] were identified as the majority of patients with LA NSCLC have mediastinal lymph node involvement. The additional code, “Abnormal findings on diagnostic imaging of lung” [R91] was included given the first suspicion of lung malignancy arises from abnormalities seen on chest x-rays or CTs, acknowledging this does not confirm diagnosis.

b. OPCS codes identified for primary diagnostic event (Additional file 2)

Codes identified as surrogates for the diagnosis of LA NSCLC included biopsies of the lung, pleura and mediastinal lymph nodes and procedures whereby specimens are obtained for cytological confirmation of malignancy. Imaging with body and head CT and PET CT are important for staging of disease and glomerular filtration rate testing is standardly performed for any patient being considered for chemotherapy.

c. OPCS codes identifying primary management (Additional file 3)

Primary management codes included those denoting treatment with radical radiotherapy (identified as intensity modulated radiotherapy [X67.1] and complex conformal radiotherapy [X67.7]) and chemotherapy. Interventional codes included endovascular stent placement [L76.9] and insertion of stent into vena cava [L79.3] (which means the patient experienced superior vena cava obstruction secondary to a locally advanced tumour in the lung apex) and required treatment with stent insertion.

d. ICD-10 codes indicating secondary site malignancies or complications from recurrent/progressive/metastatic disease (Additional file 5)

The codes identified for the diagnosis of recurrent, progressive or metastatic disease mostly included those with “Secondary & unspecified malignant neoplasm of...” as this implies that malignant disease has metastasized to this site; and codes that identified complications from metastases, such as cerebral oedema [G93.6], which can result from cerebral metastases. Additionally, there were codes that overlapped with those identifying primary presentation as recurrent and metastatic disease can present with similar complications depending on the location of disease.

e. OPCS codes identified for recurrent, progressive or metastatic disease diagnostic event (Additional file 6)

Codes identified as surrogates for the diagnosis of recurrent, progressive or metastatic disease overlapped codes for primary presentation, as biopsies are used to confirm recurrence and imaging is used to re-stage disease. Additional imaging OPCS codes included those denoting MRI spines ([U211 AND Z06.1], [U21.1 AND Z06.2], [U21.1 AND Z99.2], [U21.1 AND Z06.3]) and bone scans [U14.1], as these are not routinely done at initial staging but are performed to investigate metastases to the spine and bones, respectively.

f. OPCS codes identifying secondary management for recurrent, progressive or metastatic disease (Additional file 7)

Radiotherapy OPCS codes for “simple radiotherapy” ([X67.5], [Y91.2]) were used as they indicate that treatment is non-curative (as opposed to “complex radiotherapy” [X67.7], which indicates treatment is radical with the intention of cure). The only exception to this rule is that “Preparation for intensity modulated radiation therapy” [X67.1] (considered complex radiotherapy that is usually delivered in the radical setting) is also used to code for SABR (stereotactic ablative radiotherapy), which can be used to treat oligometastatic (single or few systemic metastases that are amenable to surgery or ablative therapy) disease.

For chemotherapy OPCS codes, only “Delivery of exclusively oral chemotherapy for neoplasm” [X73.1] is exclusive to patients being treated for recurrent or metastatic disease because there are no oral chemotherapy drugs currently used in the radical setting. The SACT data can be used in conjunction with the OPCS codes as it details the specific chemotherapy drugs delivered to patients and this information can be used to help discriminate curative or non-curative (palliative) treatment as some drug regimens are used exclusively as palliative treatment.
Interventional codes for endovascular stent placement and insertion of stent into vena cava were also included here as superior vena cava obstruction can be a complication of locally recurrent or metastatic disease requiring treatment with stent insertion.

Interval definitions for back-dating
The process of interval back-dating was used to optimize the correlation of manual and routine intervals when using proxy time points from the routine data and filter out diagnostic events that yielded negative results (Fig. 1). For the date of diagnosis, a back-dating window of 6 weeks (1.5 months) was chosen as the interval during which a diagnostic event might occur prior to the initiation of primary treatment (denoted by a relevant investigative OPCS code), or ICD10 code indicating primary diagnosis (whichever occurred earliest). If a biopsy OPCS code was available, this was taken to be the date of diagnosis, so long as it occurred within 6 weeks prior to the start of primary treatment, with no further back-dating to other investigate codes. The same backdating interval was used to identify the diagnostic events for secondary malignancy presentation prior to initiation of secondary treatment.

Correlation of these datasets were then tested on the key clinical outcome indicators of OS and PFS to establish if routine data could be used as a reliable proxy measure for manual data.

Results
Patients’ characteristics
We identified 43 consecutive patients for this pilot study, 27 of whom were men and 16 women. Patient demographics are displayed in Table 3. The median age was 67 years (range 46-89 years) and all patients had stage IIIA/B disease. The majority of patients were PS (performance status) 0–1 but for 6/43 patients the PS was not recorded and 3/43 patients had a PS of 2. 20/43 patients had the optimal cCRT (concurrent chemoradiotherapy) [16], 9/43 patients had sCRT (sequential chemoradiotherapy), 13/43 patients had radical radiotherapy alone, and 1 patient unconventionally received gefitinib followed by radical radiotherapy (Table 3).

Twenty two patients had adenocarcinomas (18 of whom had no sensitizing mutations and 3 with unknown EGFR/ALK status), 19 had squamous cell carcinomas, in 1 patient it was not possible to further differentiate the tumour beyond determining that it was a NSCLC.1 patient had no definitive invasive malignancy demonstrated on biopsy but was treated due to high clinical suspicion.

Survival and recurrence
Using the manual data, the median PFS was 10.78 months (range 1.58–37.49 months) and median OS was 16.36 months (range 2.69–37.49 months). Based on the routine data, using proxy measures, the median PFS was estimated at 10.68 months (range 1.61–31.93 months) and median OS was 16.36 months (range 2.69–37.49 months).
Table 3 Patients’ characteristics. NR (Not recorded), PS (Performance status)* (Additional file 8 [21]), EGFR (epidermal growth factor receptor), EGFR mutation (epidermal growth factor receptor with a sensitizing mutation to targeted therapy), ALK (anaplastic lymphoma kinase), Kras (K-rat sarcoma), WT (wild type) meaning no sensitizing mutations are found. cCRT (concurrent chemoradiotherapy), sCRT (sequential chemoradiotherapy). RT (radiotherapy). 4 cycles of chemotherapy are usually given. CV (cispalatin and vinorelbine), CarboV (carboplatin and vinorelbine), GCis (gemcitabine and cisplatin), GCarb (gemcitabine and carboplatin), Pemcarbo (pemetrexed and carboplatin), CisN (cispalatin and navelbine). AE (adverse event).

| Patient | Age range | PS | Stage | Histology                     | Treatment                                                                 |
|---------|-----------|----|-------|-------------------------------|---------------------------------------------------------------------------|
| 1       | 45-49y    | PS1| IIIA  | Squamous cell carcinoma       | cCRT (CVx4; 64Gy in 32#)                                                  |
| 2       | 65-69y    | PS0| IIIA  | Squamous cell carcinoma       | sCRT (GCarb × 4; 64Gy in 32#)                                             |
| 3       | 70-74y    | PS1| IIIA  | Squamous cell carcinoma       | cCRT (CV ×1-stopped due to AE; 64Gy in 32#)                                |
| 4       | 70-74y    | PS1| IIIA  | Squamous cell carcinoma       | sCRT (GCis ×4; 55 Gy in 20#)                                              |
| 5       | 80-84y    | PS1| IIIA  | Adenocarcinoma. EGFR WT       | sCRT (pemcarbo x2- stopped due to AE; 64Gy in 32#)                         |
| 6       | 55-59y    | PS1| IIIA  | Adenocarcinoma EGFR WT        | cCRT (CV ×4; 64Gy in 32#)                                                  |
| 7       | 70-74y    | PS1| IIIB  | Squamous cell carcinoma       | sCRT (GCarbo x3- stopped due to AE; 55Gy in 20#)                          |
| 8       | 65-69y    | PS0| IIIA  | Squamous cell carcinoma       | cCRT (CVx3; 55gy in 20#)                                                   |
| 9       | 65-69y    | NR | IIIA  | Squamous cell carcinoma       | RT alone: 55gy in 20#                                                      |
| 10      | 55-59y    | NR | IIIA  | Squamous cell carcinoma       | RT alone: 64Gy in 32#                                                      |
| 11      | 65-69y    | NR | IIIB  | Squamous cell carcinoma       | sCRT (GCisx2 switched to GCarbo x 2 due to AE; 64Gy in 32#)                |
| 12      | 65-69y    | NR | IIIA  | Adenocarcinoma. EGFR and ALK WT| cCRT (CV ×4, 64Gy in 32#)                                                  |
| 13      | 75-79y    | PS1| IIIA  | Adenocarcinoma. EGFR mutation | Gefitinib x6 followed by 55 in 20#                                        |
| 14      | 65-69y    | PS0| IIIA  | Adenocarcinoma. EGFR and ALK WT| cCRT (CVx1 switched to CarboV ×3 due to AE; 64Gy in 32#)                   |
| 15      | 65-69y    | PS1| IIIA  | High grade dysplasia at least; no definitive invasive malignancy | cCRT (CV ×4; 64Gy in 32#)                                                  |
| 16      | 55-59y    | PS1| IIIA  | Squamous cell carcinoma       | cCRT (CV ×2; 64Gy in 32#)                                                  |
| 17      | 70-74y    | NR | IIIB  | Adenocarcinoma. EGFR and ALK WT| RT alone: 64Gy in 32#                                                      |
| 18      | 75-79y    | PS0| IIIB  | Adenocarcinoma. EGFR and ALK WT| cCRT (CisN; 64Gyin 32#)                                                     |
| 19      | 80-84y    | PS2| IIIB  | Squamous cell carcinoma       | RT alone: 64Gy in 32#                                                      |
| 20      | 50-54y    | PS1| IIIA  | Adenocarcinoma. EGFR and ALK WT| cCRT (CV ×4; 64Gy in 32#)                                                  |
| 21      | 50-54y    | PS0| IIIA  | Adenocarcinoma. EGFR and ALK WT| cCRT (CV ×3; 64Gy in 32#)                                                  |
| 22      | 55-59y    | PS1| IIIB  | Adenocarcinoma. EGFR and ALK WT| RT alone: 64Gy in 32#                                                      |
| 23      | 70-74y    | PS1| IIIA  | Squamous cell carcinoma       | RT alone: 55Gy in 20#                                                      |
| 24      | 75-79y    | PS1| IIIA  | Adenocarcinoma. EGFR and ALK WT| sCRT (CVx4; 64Gy in 32#)                                                   |
| 25      | 80-84y    | PS1| IIIA  | PD carcinoma(no comment on EGFR/ ALK) | RT alone: 55Gy in 20#                                                      |
| 26      | 60-64y    | PS0| IIIA  | Adenocarcinoma. EGFR and ALK WT| sCRT (CV ×2 switched to CarboV ×2 due to AE; 64Gy in 32#)                  |
| 27      | 80-84y    | PS0| IIIA  | Squamous cell carcinoma       | cCRT (CV ×4; 64Gy in 32#)                                                  |
| 28      | 45-49y    | PS1| IIIB  | Squamous cell carcinoma       | cCRT (CV ×4; 64Gy in 32#)                                                  |
| 29      | 65-69y    | PS1| IIIA  | Squamous cell carcinoma       | cCRT (CarboVx3; 64Gy in 32#)                                               |
| 30      | 45-49y    | PS1| IIIA  | Adenocarcinoma-insufficient material for ALK/EGFR testing | sCRT (cispem ×4; 64Gy in 32#)                                              |
| 31      | 65-69y    | PS0| IIIA  | Adenocarcinoma. EGFR and ALK WT| cCRT (CV ×4; 64Gy in 32#)                                                  |
| 32      | 60-64y    | PS1| IIIA  | Adenocarcinoma. EGFR and ALK WT| sCRT (cispem2 switched to CV ×2 due to AE; 64Gy in 32#)                    |
| 33      | 60-64y    | PS1| IIIA  | Squamous cell carcinoma       | cCRT (CV ×4; 64Gy in 32#)                                                  |
| 34      | 70-74y    | PS1| IIIB  | Squamous cell carcinoma       | RT alone: 64Gy in 32#                                                      |
OS was estimated at 15.38 months (range 2.14–33.71 months) (Fig. 2a and b).

The routine methodology failed to detect 4 recurrences and 3 deaths resulting in increased censoring of events and a separation of the curves that was not statistically significant for either endpoint.

Data correlation

Overall the routine data underestimated the PFS (manual (mean = 13.88 months, SD = 9.31); routine (mean = 13.79 months, SD = 8.95) and OS (manual (mean = 16.49 months, SD = 9.33); routine (mean = 15.48 months, SD = 9.17) of the manual data. A paired sample t-test for the mean PFS showed a difference of 0.09 months (p = 0.86; 95% confidence interval –0.86–1.03) and 1.02 months (p = 0.00; 95% confidence interval 0.34–1.69) for the difference in the mean OS. However, there was good overall correlation of 0.94 (p = 0.00, 95% confidence interval 0.90–0.97) for PFS (Fig. 3a) and 0.97 (p = 0.00, 95% confidence interval 0.95–0.98) for OS (Fig. 3b).

The routine methodology correctly identified 32/43 routine diagnosis dates to within 2 weeks accuracy of the manual diagnosis dates, and of those, 21/43 dates matched exactly. 5/43 routine diagnosis dates were earlier than the manual dates (ranging from 1 to 6 days earlier). 5/43 routine diagnosis dates were outside of 2 weeks but within 4 weeks of the manual data; and for 6/43 patients, there was a > 28 day difference in routine and manual diagnosis dates, with the routine dates occurring later than the manual. 3 patients had a difference in diagnosis dates of > 100 days. Whilst the paired sample t-test showed that routine data tend to suggest later diagnosis dates compared to that identified by manual data (t = –2.45; p = 0.02) and the overall correlation was 0.98 (p = 0.00, 95% confidence interval 0.96–0.99) (Fig. 3c).

The sensitivity and specificity of using routine data instead of manual data to determine recurrences was 0.75 and 1, respectively, 12/16 recurrences were correctly detected when assessing the routine data alone. 4/16 routine recurrence dates were within 2 weeks of the manual diagnosis dates, and of those, 3/16 dates matched exactly. 6/16 routine diagnosis dates were outside of 4 weeks but less than 100 days of the manual data. For 2/16 patients, there was a > 100 day difference in routine and manual diagnosis dates (Fig. 3a).

The sensitivity and specificity of using routine data instead of manual data to determine death event was 0.81 and 1, respectively. 13/16 death events were correctly detected on the routine data and of those, 12/13 dates of death matched exactly and for the remaining other patient, the routine date fell within 1 week of the manual death date. For 27 patients who were still alive at the time of assessment and for whom the last clinical encounter was used as the end- interval, the manual and routine dates matched exactly for 24/27 patients (Fig. 3b).

For patients 13 and 11, diagnosis and chemotherapy (as part of sCRT) were initiated in other hospitals and followed-up continued there, resulting in missing clinical episodes on routine data but detection on manual data (as clinical correspondence letters were available). The result was later routine diagnosis dates and shorter overall routine PFS and OS. Patient 36 similarly continued follow-up in another hospital. For patients 23 and 6 a late routine diagnosis date resulted from positive diagnostic investigations falling outside the 6 week
back-dating interval from treatment and alternative surrogates being used, resulting in a shorter PFS and OS. For patient 38, the routine PFS was shorter as recurrence was not detected on routine data due to individualised treatment which was not listed as a standard treatment code.

Discussion
In this pilot study, we analyzed the PFS and OS for 43 patients with LA NSCLC treated in our regional referral centre in north London over a 2 year period. The results suggest that routine data can potentially be used to reliably estimate survival outcomes for patients with LA NSCLC treated with primary radical radiotherapy. This method relies on identifying relevant ICD-10 and OPCS codes that are used as surrogates for diagnosis and recurrence dates followed by a refining process that involves back-dating interval optimization to improve correlation.

There are some crucial considerations in defining the key time points both for the manual data and routine data interpretation: 1. Manual diagnosis dates: These followed a hierarchy with imaging following the preferred diagnostic biopsy date due to certain limitations: Whilst imaging can give a strong indication of

Fig. 2 a Kaplan Meier Curve for PFS (in months). Survival curves for the routine (green line) and manual (blue line) data are shown. 27/43 events censored from the manual data and 31/43 events censored from the routine data. Wilcoxon signed-ranks test statistic 1.10, p(0.29). b Kaplan Meier Curve for OS (in months). Survival curves for the routine (green line) and manual (blue line) data are shown. 27/43 events censored from the manual data and 30/43 events censored from the routine data. Wilcoxon signed-ranks test statistic 0.08, p(0.78)
malignancy, patients with lung cancer often have background lung disease that makes them prone to recurrent chest infections. Radiological changes seen during active chest infections make identifying malignancy less reliable. This is in contrast to identifying recurrence and/or metastatic disease when malignancy is already known, and diagnosis is often done radiologically without repeat biopsies, unless diagnosis is uncertain. 2. Manual and routine recurrence interval dates: Taken to be the date of progression, recurrence, metastases, death, or last known clinical encounter (if no progression occurred) for practical reasons - so that events would be reached. 3. Identifying secondary treatment in routine data: Any therapy starting after a 10 week interval from the last day of radiotherapy or chemotherapy (whichever was completed last) was chosen as an indicator of secondary treatment because it is standard practice for patients to have reassessment imaging at 8–12 weeks following completion of treatment. At this point, progressive or metastatic disease can be observed so a 10 week interval was selected as a compromise - too short an interval might pick up delayed primary treatment events, and too long an interval might miss the start of secondary treatment.

OS and PFS values derived from our routine data methodology correlated well with that derived from the gold standard manual data with the Wilcoxon signed-rank test results suggesting no statistically significant difference between the survival curves when assessed by manual versus routine data. Based on the manual data, the median PFS and OS was 10.78 months and 16.36 months, respectively. Using the proxy measures from the routine data, the estimated median PFS and OS was 10.68 months and 15.38 months, respectively. The paired sample t-tests showed the difference in the mean PFS to be small and non-significant but the difference in the mean OS to be larger and significant. However, these results correlated well overall with the manual data, giving a statistically significant correlation coefficient of 0.94 for PFS and 0.97 for OS. The high sensitivity and specificity of our method indicate that analyzing routine
data does not tend to falsely identify recurrence or death events so survival estimates are less likely to be underestimated.

All discrepancies between the manual and routine data sets could be attributed to 1. Missing or inaccurately entered OPCS or ICD10 codes due to a) patients having diagnosis and/or recurrence detected with treatment initiation in other hospitals b) codes appearing on patients’ admission dates rather than the dates of the procedures themselves or c. treatment of recurrence being non-standard (eg. oligometastatic disease being treated surgically) and 2. Delays in initiation of treatment beyond the NHS England target of 31 days due to, for example, patients becoming unwell, resulting in alternative surrogates having to be used for dates of diagnosis or recurrence. The reasons for deaths escaping detection on routine data were mostly unclear although 1 patient died abroad, a situation that is perhaps less reliably updated on to the system. However, there is a time lag between the occurrence of death and its record being updated on the system, and it is possible that this affected the ability to detect death events on routine data. These all led to late diagnosis dates, late or absent recurrence dates, and/or absent death dates and subsequently inaccurately calculated PFS and OS. Although this resulted in an increased censoring of events and a separation of the survival curves, the differences were not statistically significant (Fig. 2a and b).

Our back-dating strategy, used to optimize correlation between manual and routine primary diagnosis and recurrence event dates, utilized time intervals tailored to reflect clinical practice and the clinical target times set out by NHS England (2013). This framework recommends that the maximum time from diagnosis to first definitive treatment is 1 month (or 31 days); and that for all subsequent treatments for new cases or primary and recurrent cancer, the maximum time interval is 1 month (or 31 days). Therefore, ICD10 codes consistent with a primary diagnosis or recurrent, progressive or metastatic disease, are likely to be preceded by diagnostic investigation codes within a period of up to 31 days. A longer interval of 6 weeks was chosen to avoid potentially missing relevant investigative and diagnostics flag for patients who may have started treatment beyond the 31 day target. This meant we still captured patients who may have had delays in starting treatment due to 1. patients’ choice 2. becoming unwell 3. radiotherapy replanning requirements resulting from significant changes in anatomy or 4. inability to start in the preferred time period due to patient load exceeding treatment capacity at that time.

The completeness of recorded information is a fundamental limitation of both manual and routine data. Manual data not only most reliably determines outcome measures but contains important details such as histological subtype, mutation status, lung function, detailed smoking status (ex-smoker, recent ex-smoker, and quantification by pack-years), response to treatment demonstrated on CT (stable disease, partial response, progressive disease), and grading of side effects from treatment. At present such information can only be identified in manual data as these are not coded in routine data. However, clinical outcome measures can be inferred or used as proxy indicators. For example, it would be reasonable to assume that ICD10 codes for oesophagitis or neutropenia in a patient receiving chemotherapy and radiotherapy might be experiencing these side effects as a direct result from their treatment. The caveat is that there may be confounding factors or comorbidities causing these problems, the severity of these side effects are not coded, and the absence of these ICD-10 codes does not mean they were not experienced. Adverse effects from treatment have an important impact on patients’ ability to complete treatment and their quality of life.

Additional limitations include potentially confusing routine information for patients who have other synchronous or metachronous malignancies (eg. head and neck and bladder cancers) where recurrences and treatment may occur. For these patients with dual pathology, where “Secondary & unspecified malignant neoplasm of” or “Secondary malignancy of-” codes appear in the HES data, referring to the RTDS and SACT data can help distinguish if treatment is being initiated for disease relating to the lung cancer or to the other malignancy as 1) the RTDS data will state the site being treated and the relevant ICD-10 diagnosis code relating to that treatment (eg. Pelvic metastases from a lung cancer primary) will have “pelvis” documented as the treatment site and an ICD10 code denoting a lung cancer (primary) 2) the SACT data would inform us as to what chemotherapy is being delivered (which, in itself, might be indicative of the primary, if the regime is exclusive to lung cancer) and the primary diagnosis relating to that chemotherapy regime.

Interestingly, although it is well recognized that PS impacts OS [2, 15, 17], is used to help determine the most appropriate management course [18], and is required to be recorded in manual and routine databases, this appears to be poorly recorded in both. This perhaps reflects a view that the usefulness of a PS score is limited by the degree of subjectivity and inter-observer variability in assessment [17, 19].

There has been a recognized need to improve the quality of routine data in order to broaden its clinical application. An example of one such database developed for quality improvement is the Cancer Outcomes and Service Dataset (COSD) that has recently
been introduced as the new national standard for reporting cancer in the NHS in England, having replaced the National Cancer Dataset. This system will enable the clinical details and outcomes from multidisciplinary team meetings (where all patients diagnosed with and being considered for cancer treatment are discussed) to be entered into COSD. This has begun to be in use in our hospital and one of the changes this will have on outcomes analysis will be to ascertain a more accurate diagnosis date.

In addition, national cancer strategies [4, 20] have placed increasing emphasis on recording of clinical outcome measures to help monitor if national targets are being met which will drive the enrichment of the available clinical databases, and focus more attention on developing methods to analyse routine datasets. This will not only promote the clinical usefulness of routine data for survival outcomes but potentially for treatment toxicity and patient-screening for entry into trials.

Future work includes integrating new national datasets and testing our method on a larger cohort to see if accuracy can be improved. Whilst the identified event flags used as proxy measures and the chosen back-dating intervals reflect our local practice, we have deliberately ensured they are not specific to it such that this method is transferable to other centres. As the management of NSCLC in the UK is standardized by NICE guidelines any nuances in practice across the country are unlikely to limit the application of this technique although adjustments for optimization may be required. Once this technique has been sufficiently refined, a computational algorithm will be developed to automate this process such that large scale routine data can be processed more efficiently.

Conclusions
This is a novel approach that uses routine datasets to determine outcome indicators in patients with LA NSCLC that has the potential to be a reliable surrogate to analyse manual data, having demonstrated a Pearson correlation coefficient of 0.94 for PFS, and 0.97 for OS. An algorithm is being developed to enable automated interpretation of routine datasets for patients with LA NSCLC and is being refined to improve data correlation. The clinical application of automated routine data interpretation goes beyond assessing survival data in LA NSCLC, and can be tailored to auto-analyse outcomes for other stages of NSCLC and/or other tumour types. The ability to enable efficient and large scale analysis of current lung cancer strategies has a huge potential impact on the healthcare system.

Additional files

Additional file 1: Lung Cancer Staging (AJCC 7th Ed): Table describing the TNM lung cancer staging. (DOCX 18 kb)
Additional file 2: OPCS codes identified for primary presentation and investigation: Table listing biopsy OPCS codes, other diagnostic procedure OPCS codes, diagnostic imaging OPCS codes and RTDS indicators. (DOCX 18 kb)
Additional file 3: OPCS codes identifying primary management: Table listing radiotherapy OPCS codes, chemotherapy OPCS codes and interventional OPCS codes. (DOCX 17 kb)
Additional file 4: ICD-10 codes indicating primary site lung malignancies: Table listing ICD-10 codes indicating primary site lung malignancy. (DOCX 17 kb)
Additional file 5: ICD-10 codes indicating secondary site malignancies or complications from recurrent/progressive/metastatic disease: Table listing ICD-10 codes indicating secondary site malignancies and ICD-10 codes indicating complications from disease. (DOCX 18 kb)
Additional file 6: OPCS codes identified for recurrent, progressive or metastatic disease presentation and investigation: Table listing diagnostic procedure OPCS codes, diagnostic imaging OPCS codes and RTDS indicators. (DOCX 19 kb)
Additional file 7: OPCS codes identifying secondary management: Table listing radiotherapy OPCS codes, chemotherapy OPCS codes and interventional OPCS codes. (DOCX 18 kb)
Additional file 8: ECOG/WHO Performance Status: Table describing ECOG/WHO Performance status grades used to reflecting patients’ fitness. (DOCX 15 kb)

Abbreviations
AE: Adverse event; ALK: Anaplastic lymphoma kinase; cCRT: Concurrent chemoradiotherapy; COSD: Cancer outcomes and service dataset; CT: Computed tomography; ECOG: Eastern Cooperative Oncology Group; EGFR: Epidermal growth factor receptor; HES: Hospital episodes statistic; ICD 10: International classification of diseases; LA NSCLC: Locally advanced non-small cell lung cancer; MDT: Multidisciplinary team; OPCS: Office of population censuses and surveys classification of surgical operations and procedures – a Classification of Interventions and Procedures; PDS: Personal demographics service; PET: CT: Positron emissions tomography CT; PS: Performance status; RT: Radiotherapy; RTDS: Radiotherapy database system; SABR: Stereotactic ablative radiotherapy; SACT: Systemic anti-cancer therapy; sCRT: Sequential chemoradiotherapy

Acknowledgements
Dr Swee-Ling Wong is supported by a Cancer Research UK Centres Network Accelerator Award Grant (A21993) to the ART-NET consortium. The authors gratefully acknowledge infrastructure support from the Cancer Research UK University College London and Imperial Centres and the National Institute for Health Research Imperial Biomedical Research Centre. We also gratefully acknowledge our Professor of Statistical Methods for Medicine, Ian White, for his contribution to our statistical analyses. This research uses data provided by patients and collected by the NHS as part of their care and treatment. A pilot study of this work, involving 20 patients, was presented as a poster at the 14th Annual British Thoracic Oncology Group Conference 2016 and the poster abstract published in the Lung Cancer, volume 91, supplement 1, S40 (114).

Funding
This research is currently not funded.

Availability of data and materials
The data that support the findings of this study are available from University College London Hospital Informatics Department but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of University College London Hospital Informatics Department.
Authors’ contributions
SW designed the mechanism of using routine data as a surrogate for manual data to assess outcomes of patients with locally advanced non-small cell lung cancer; collected and analysed the data; as well as being the primary author of this manuscript.KR aided the design of this mechanism of using routine data as a surrogate for manual data to assess outcomes of patients with locally advanced non-small cell lung cancer. KR significantly contributed to the critical revision of this manuscript. GR is a supervisor, aided the design of this mechanism, and was involved in drafting and revising the manuscript critically for important intellectual content. MW conceived the original idea of this mechanism, and was involved in drafting and revising the manuscript critically for important intellectual content. RM is a supervisor, aided the design of this mechanism, contributed to drafting the manuscript and gave the final approval of the version to be published. All authors read and approved the final manuscript.

Ethics approval and consent to participate
No consent or research ethics committee review for approval was required as confirmed by the Health Research Committee Service as research fits the criteria of “Research involving previously collected, non-identifiable information” which states that “Research limited to secondary use of information previously collected in the course of normal care (without an intention to use it for research at the time of collection) is generally excluded from REC review, provided that the patients or service users are not identifiable to the research team in the course of normal care (without an intention to use it for research at the time of collection) is generally excluded from REC review, provided that the patients or service users are not identifiable to the research team in carrying out the research.” No administrative permissions were required in order to review patient records and use the data as they fit the additional criteria that “This exception also applies to research undertaken by staff within a care team using information previously collected in the course of care for their own patients or clients, provided that data is anonymized or pseudonymised in conducting the research.”

Consent for publication
Not applicable. All patient data has been anonymized with no details on individuals reported within the manuscript.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Clinical Oncology, University College London Hospital, 235 Euston Road, London NW1 2BU, UK. 2Division of Surgery and Interventional Science, University College London, London, UK. 3Department of Medical Physics and Biomedical Engineering, University College London, London, UK. 4Department of Clinical Oncology, Charing Cross Hospital, Fulham Palace Road, London, UK. 5Computational Oncology Group, Institute for Global Health Improvement, Imperial College, London, UK.

Received: 26 October 2016 Accepted: 16 March 2018
Published online: 11 April 2018

References
1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and sun worshipping. Mayo Clin Proc. 2008;83(5):584–94.
2. Verdecchia A, et al. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8(9):784–96.
3. Coleman M, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer benchmarking partnership): an analysis of population-based. Lancet. 2011;377(9760):127–38.
4. Cancer Research UK. Vision for radiotherapy 2014–2024, 2014.
5. Kom R, Crowley J. Overview: progression-free survival as an endpoint in clinical trials with solid tumors. Clin Cancer Res. 2013;19(10):2607–12.
6. Saad ED, Katz A. Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined: Ann Oncol. 2009;20(3):460–4.
7. Kane R, Welling S, Free C, Goodrich J. Uses of routine data sets in the evaluation of health promotion interventions: opportunities and limitations. Health Educ. 2000;100(1):33–41.
8. Coory M, Thompson B, Baade P, Fritschi L. Utility of routine data sources for feedback on the quality of cancer care: an assessment based on clinical practice guidelines. BMC Health Serv Res. 2009;9:84.
9. Hewitt M, Simone J. Ensuring quality cancer care. National Cancer Policy Board, Institute of Medicine and National Research Council. Washington: National Academies Press; 1999.
10. Jamtvedt G, Young JM, Kristoffersen DT, O’Brien MA, Oxman AD. Audit and feedback: effects on professional practice and health care outcomes. In G. Jamtvedt (Ed.), Cochrane Database of Systematic Reviews. Chichester, UK. Wiley. https://doi.org/10.1002/14651858.CD000359.pub2. 2006.
11. Jha RDAK, Perlin JB, Kizer KW. Effect of the transformation of the veterans affairs health care system on the quality of care. N Engl J Med. 2003;348:2218–27.
12. Trivedi A, Zaslavsky A, Schneider E, et al. Trends in the quality of care and racial disparities in Medicare managed care. New Engl J Med. 2005;353:692–700.
13. Ricketts K, Williams M, Liu Z, Gibson A. Automated estimation of disease recurrence in head and neck cancer using routine healthcare. Comput Methods Prog Biomed. 2014;117(3):412–24.
14. Liu Z, Fitzke H, Williams M. Using routine data to estimate survival and recurrence in head and neck cancer: our preliminary experience in twenty patients. Clin Otolaryngol. 2013;38(4):334–9.
15. Rich AL, et al. Lung cancer in England: information from the National Lung Cancer Audit (LUCA): Lung Cancer. 2011;7(2):16–22.
16. O’Rourke N, Roqué i Figuls M, Fareé Bernadó N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database of Systematic Reviews. Issue 6. Art. No.: CD002140. doi: https://doi.org/10.1002/14651858.CD002140.pub3. 2010.
17. Blagden SP, Charman SC, Sharples LD, Magee LRA, Gilligan D. Performance status score: do patients and their oncologists agree? Br J Cancer. 2003; 89(6):1022–7.
18. Lung cancer. The diagnosis and treatment of lung cancer. NICE Clin. Guidel. 2011;121:41.
19. Sørensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer. 1993;67(6):773–5.
20. Everyone Counts: Planning for patients 2014/15 to 2018/19, NHS, 1–90, 2013.
21. Oken CP, NW CRH, Torney DC, Horton J, Davis TE, McDadden ET. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. Oncolc. 1982;5(6):649–55.